CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 146 filers reported holding CLOVIS ONCOLOGY INC in Q4 2014. The put-call ratio across all filers is 0.43 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $2,700,000 | +52.5% | 60,785 | +23.8% | 0.00% | +50.0% |
| Q3 2016 | $1,770,000 | +697.3% | 49,093 | +203.4% | 0.00% | – |
| Q2 2016 | $222,000 | -76.8% | 16,182 | -67.5% | 0.00% | -100.0% |
| Q1 2016 | $955,000 | -41.3% | 49,747 | +7.2% | 0.00% | -50.0% |
| Q4 2015 | $1,626,000 | -93.3% | 46,415 | -82.3% | 0.00% | -92.3% |
| Q3 2015 | $24,151,000 | +8.1% | 262,626 | +3.3% | 0.03% | +13.0% |
| Q2 2015 | $22,347,000 | +32.2% | 254,290 | +11.6% | 0.02% | +35.3% |
| Q1 2015 | $16,909,000 | -3.6% | 227,799 | -27.3% | 0.02% | -5.6% |
| Q4 2014 | $17,542,000 | +24.0% | 313,262 | +0.5% | 0.02% | +28.6% |
| Q3 2014 | $14,143,000 | +2113.3% | 311,806 | +1919.1% | 0.01% | +1300.0% |
| Q2 2014 | $639,000 | -60.7% | 15,443 | -34.2% | 0.00% | -50.0% |
| Q1 2014 | $1,626,000 | +102.7% | 23,477 | +76.4% | 0.00% | +100.0% |
| Q4 2013 | $802,000 | -85.9% | 13,307 | -85.8% | 0.00% | -83.3% |
| Q3 2013 | $5,701,000 | -59.2% | 93,776 | -55.1% | 0.01% | -60.0% |
| Q2 2013 | $13,988,000 | – | 208,827 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 3,402,781 | $231,389,000 | 9.96% |
| Versant Venture Management, LLC | 101,855 | $6,926,140,000 | 7.29% |
| Avoro Capital Advisors LLC | 1,102,884 | $74,996,000 | 4.86% |
| Redmile Group, LLC | 1,320,027 | $89,762,000 | 3.90% |
| NEXTHERA CAPITAL LP | 233,200 | $15,858,000 | 2.92% |
| Iguana Healthcare Management, LLC | 60,000 | $4,080,000 | 2.66% |
| HealthCor Management, L.P. | 973,840 | $66,221,000 | 2.16% |
| Casdin Capital, LLC | 127,500 | $8,670,000 | 2.11% |
| Prosight Management, LP | 40,000 | $2,720,000 | 2.00% |
| Camber Capital Management LP | 600,000 | $40,800,000 | 2.00% |